Results 11 to 20 of about 9,896 (218)

The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy. [PDF]

, 2011
BackgroundTumor microenvironments present significant barriers to penetration by antibodies and immunoconjugates. Tumor microenvironments, however, are difficult to study in vitro.
Broaddus, V Courtney, Feng, Mingqian, Fitzgerald, David, Hassan, Raffit, Ho, Mitchell, Nagashima, Kunio, Phung, Yen, Xiang, Xinran, Zhang, Jingli   +8 more
core   +6 more sources

Enhanced cytotoxicity of a Pseudomonas Exotoxin A based immunotoxin against prostate cancer by addition of the endosomal escape enhancer SO1861

Frontiers in Pharmacology, 2023
Immunotoxins consist of an antibody or antibody fragment that binds to a specific cell surface structure and a cytotoxic domain that kills the cell after cytosolic uptake. Pseudomonas Exotoxin A (PE) based immunotoxins directed against a variety of tumor
Anie P. Masilamani, Anie P. Masilamani, Nathalie Huber, Nathalie Huber, Constanze Nagl, Constanze Nagl, Viviane Dettmer-Monaco, Viviane Dettmer-Monaco, Viviane Dettmer-Monaco, Gianni Monaco, Gianni Monaco, Gianni Monaco, Gianni Monaco, Isis Wolf, Isis Wolf, Isis Wolf, Susanne Schultze-Seemann, Susanne Schultze-Seemann, Sanaz Taromi, Sanaz Taromi, Sanaz Taromi, Christian Gratzke, Christian Gratzke, Hendrik Fuchs, Philipp Wolf, Philipp Wolf   +25 more
doaj   +1 more source

A double safety lock tumor-specific device for suicide gene therapy in breast cancer [PDF]

, 2020
Producción CientíficaThe complexity and continuous evolution of cancer make the design of novel strategies of treatment a constant challenge in biomedicine.
Arias Vallejo, Francisco Javier, Girotti, Alessandra, Muñoz Martínez, Raquel, Piña Lancho, María Jesús, Rodríguez Cabello, José Carlos, Serrano, Sofía   +5 more
core   +2 more sources

Combination treatments with the PKC inhibitor, enzastaurin, enhance the cytotoxicity of the anti-mesothelin immunotoxin, SS1P. [PDF]

PLoS ONE, 2013
Activated protein kinase C (PKC) contributes to tumor survival and proliferation, provoking the development of inhibitory agents as potential cancer therapeutics.
Abid R Mattoo, Ira Pastan, David Fitzgerald   +2 more
doaj   +1 more source

Targeted delivery of immunotoxin by antibody to ganglioside GD3: a novel drug delivery route for tumor cells. [PDF]

PLoS ONE, 2013
Gangliosides are sialic acid-containing glycolipids expressed on plasma membranes from nearly all vertebrate cells. The expression of ganglioside GD3, which plays essential roles in normal brain development, decreases in adults but is up regulated in ...
Vanina Torres Demichelis, Aldo A Vilcaes, Ramiro Iglesias-Bartolomé, Fernando M Ruggiero, Jose L Daniotti   +4 more
doaj   +1 more source

Novel Chemokine-Based Immunotoxins for Potent and Selective Targeting of Cytomegalovirus Infected Cells [PDF]

, 2017
Immunotoxins as antiviral therapeutics are largely unexplored but have promising prospective due to their high selectivity potential and their unparalleled efficiency.
Jeppesen, Mads G., Kledal, Thomas N., Krzywkowski, Karen, Malmgaard-Clausen, Mikkel, Rosenkilde, Mette M., Spiess, Katja   +5 more
core   +8 more sources

Second line therapy in malignant pleural mesothelioma: a systematic review [PDF]

, 2015
After the implementation of standard first line chemotherapy with platinum and antifolates in pleural mesothelioma, patients are confronted with a need for second line treatment at relapse or progression.
Baas, Paul, Buikhuisen, Wieneke A, Hiddingab, Birgitta I, Van Meerbeeck, Jan   +3 more
core   +2 more sources

GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer. [PDF]

, 2014
The emergence of targeted cancer therapy has been limited by the paucity of determinants which are tumor-specific and generally associated with disease, and have cell dynamics which effectively deploy cytotoxic payloads.
Berman-Booty, Lisa D, Magee, Michael Sullivan, Marszalowicz, Glen P, Merlino, Dante, Snook, Adam E, Waldman, Scott A   +5 more
core   +6 more sources

Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo

Frontiers in Oncology, 2022
Targeted therapies hold promise for efficiently and accurately delivering cytotoxic drugs directly to tumor tissue to exert anticancer effects. CD47 is a membrane protein expressed in a variety of malignant tumors and hematopoietic cells, which plays a ...
Zu-Chian Chiang, Zu-Chian Chiang, Zu-Chian Chiang, Shubin Fang, Yang-kun Shen, Dongya Cui, Huanjiao Weng, Dawei Wang, Yuxiang Zhao, Jizhen Lin, Jizhen Lin, Qi Chen   +11 more
doaj   +1 more source

Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas [PDF]

, 2005
Introduction: ScFv(FRP5)-ETA is a recombinant antibody toxin with binding specificity for ErbB2 (HER2). It consists of an N-terminal single-chain antibody fragment (scFv), genetically linked to truncated Pseudomonas exotoxin A (ETA).
Gunter von Minckwitz, Sebastian Harder, Sascha Hövelmann, Elke Jäger, Salah-Eddin Al-Batran, Sibylle Loibl, Akin Atmaca, Christian Cimpoiasu, Antje Neumann, Aklil Abera, Alexander Knuth, Manfred Kaufmann, Dirk Jäger, Alexander B Maurer, Winfried S Wels, MA Olayioye, Y Yarden, J Mendelsohn, DJ Slamon, CL Vogel, I Pastan, W Wels, RJ Kreitman, W Wels, W Wels, IM Harwerth, BH Iglewski, A Keppler-Hafkemeyer, M Schmidt, A Spyridonidis, M Azemar, L Wang, U Altenschmidt, M Maurer-Gebhard, JK Batra, Y Reiter, LH Pai-Scherf, M Azemar, WMA, M Maurer-Gebhard, FDA, J Schumann, M Onda, NJ Olsen, YL Yip, B Gerstmayer, DL Keefe, HS Cho, RJ Kreitman, RJ Kreitman   +49 more
core   +1 more source